Patient characteristics
| . | VTD (n = 169) . | VCD (n = 169) . |
|---|---|---|
| Male/female | 103/66 | 108/61 |
| Median age (range) | 59 (34-65) | 60 (26-65) |
| β2-microglobulin, mg/L (range) | 3.6 (2.1-8.9) | 3.8 (2.0-9.3) |
| Albumin, g/L (range) | 36.9 (28.2-41.7) | 35.7 (27.9-41.3) |
| International Staging System | ||
| ISS1 | 38 (22%) | 43 (25%) |
| ISS2 | 94 (56%) | 90 (53%) |
| ISS3 | 37 (22%) | 36 (21%) |
| No t(4;14), no17p | 137 (81%) | 140 (83%) |
| t(4;14) and/or 17p | 32 (19%) | 29 (17%) |
| Creatinine level, mmol/L, median (range) | 75 (38-170) | 79 (20-163) |
| Hemoglobin level, g/dL, median (range) | 11.2 (6.6-16.6) | 11 (8-16.6) |
| Calcium level, mmol/L, median (range) | 2.34 (2.05-3.5) | 2.37 (2.0-3.61) |
| Platelet count, ×109/L, median (range) | 253 (110-350) | 229 (105-380) |
| . | VTD (n = 169) . | VCD (n = 169) . |
|---|---|---|
| Male/female | 103/66 | 108/61 |
| Median age (range) | 59 (34-65) | 60 (26-65) |
| β2-microglobulin, mg/L (range) | 3.6 (2.1-8.9) | 3.8 (2.0-9.3) |
| Albumin, g/L (range) | 36.9 (28.2-41.7) | 35.7 (27.9-41.3) |
| International Staging System | ||
| ISS1 | 38 (22%) | 43 (25%) |
| ISS2 | 94 (56%) | 90 (53%) |
| ISS3 | 37 (22%) | 36 (21%) |
| No t(4;14), no17p | 137 (81%) | 140 (83%) |
| t(4;14) and/or 17p | 32 (19%) | 29 (17%) |
| Creatinine level, mmol/L, median (range) | 75 (38-170) | 79 (20-163) |
| Hemoglobin level, g/dL, median (range) | 11.2 (6.6-16.6) | 11 (8-16.6) |
| Calcium level, mmol/L, median (range) | 2.34 (2.05-3.5) | 2.37 (2.0-3.61) |
| Platelet count, ×109/L, median (range) | 253 (110-350) | 229 (105-380) |